Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg C N
Department of Urology, CTO Hospital, Rome, Italy.
J Urol. 1995 Dec;154(6):2054-8.
We performed a retrospective long-term study to evaluate the results of immunotherapy in the treatment of high grade superficial bladder tumors.
Between 1981 and 1993, 593 patients with superficial transitional cell carcinoma of the bladder underwent transurethral resection. Of 64 patients with stage T1 grade 3 disease 50 received intravesical bacillus Calmette-Guerin after transurethral resection of all visible tumor.
At a median followup of 42 months (range 12 to 112) 36 patients (72%) are disease-free and have not required further treatment. Superficial recurrence was noted in 8 patients (16%). Disease progressed in 6 patients (12%), including 5 with locally invasive and 1 with metastatic disease. Cystectomy was performed for progression in 4 patients and for recurrent stage T1 grade 3 disease in 1. There was 1 disease related death (2%). The overall survival rate is 94%.
Intravesical bacillus Calmette-Guerin appears to be the most effective conservative treatment for patients with stage T1 grade 3 bladder cancer.
我们进行了一项回顾性长期研究，以评估免疫疗法治疗高级别浅表性膀胱肿瘤的效果。
1981年至1993年间，593例膀胱浅表性移行细胞癌患者接受了经尿道切除术。64例T1期3级疾病患者中，50例在经尿道切除所有可见肿瘤后接受了膀胱内卡介苗治疗。
中位随访42个月（范围12至112个月），36例患者（72%）无疾病且无需进一步治疗。8例患者（16%）出现浅表复发。6例患者（12%）疾病进展，其中5例为局部浸润性疾病，1例为转移性疾病。4例患者因疾病进展接受了膀胱切除术，1例因复发性T1期3级疾病接受了膀胱切除术。有1例与疾病相关的死亡（2%）。总生存率为94%。
膀胱内卡介苗似乎是T1期3级膀胱癌患者最有效的保守治疗方法。
